Inspire Wins North Carolina Health & Life Sciences Award for Cystic Fibrosis Development Program

• Press Release
• Source: Inspire Pharmaceuticals, Inc.
• On 7:00 am EDT, Wednesday September 9, 2009

DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH - News) announced today it received the North Carolina Health & Life Sciences Award in the category of “Breakthrough Research” for its denufosol tetrasodium program for cystic fibrosis (CF). This award recognizes innovative research that has the potential to solve problems of great importance to science or society. Inspire received the award at the annual Dinner of Champions, which celebrates leaders in the health and life sciences fields, hosted by the Eastern North Carolina chapter of the National Multiple Sclerosis Society.

Related Quotes

Symbol	Price	Change
ISPH	5.94	+0.15

{"s" : "isph","k" : "c10,l10,p20,t10","o" : "","j" : ""}

“We are honored to receive this award for Inspire’s dedicated research and development of denufosol, a novel compound designed specifically for the treatment of CF lung disease. We believe denufosol has the potential to make an important difference in the lives of CF patients as an early intervention treatment that targets the underlying CF defect. Inspire was founded based on ground-breaking research by scientists at the University of North Carolina at Chapel Hill. We have since developed and advanced the denufosol program to its current Phase 3 clinical testing stage,” stated Christy L. Shaffer, Ph.D., President and CEO of Inspire.

About Inspire

Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire’s goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical and scientific expertise. The most advanced compounds in Inspire’s clinical pipeline are Prolacria^™ for dry eye and denufosol tetrasodium for cystic fibrosis, which are both in Phase 3 development and AzaSite^® for blepharitis, which is in Phase 2 development. Inspire receives revenues related to the promotion of AzaSite for bacterial conjunctivitis, the co-promotion of Elestat^® for allergic conjunctivitis and royalties based on net sales of Restasis^® for dry eye. For more information, visit www.inspirepharm.com.

Forward-Looking Statements

The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. These statements are based upon the current beliefs and expectations of Inspire’s management and are subject to significant risks and uncertainties. Specifically, there can be no assurance that Inspire’s ongoing clinical trial regarding denufosol will be successful, that the U.S. Food and Drug Administration (FDA) will approve denufosol even if the ongoing clinical trial is successful or that denufosol will make an important difference in the lives of CF patients as an early intervention treatment that targets the underlying CF defect; or that Inspire will be able to build and commercialize a sustainable portfolio of innovative new products based on its technical and scientific expertise. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, intellectual property rights, competitive products, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and content of decisions made by regulatory authorities, including the FDA. Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof.

Investor Contact:
Inspire Pharmaceuticals, Inc.
Jenny Kobin
VP, Investor Relations and Corporate Communications
919-941-9777, Extension 219
or
Media Contact:
Inspire Pharmaceuticals, Inc.
Cara Amoroso
Manager, Corporate Communications
919-941-9777, Extension 266